UCB to Sell Established Brands in India to Dr. Reddy’s

Belgium's UCB has agreed to sell its established brands in India, including its franchises in the areas of allergies and respiratory disorders, to Dr. Reddy's Laboratories for INR 8 billion, about €118 million. Revenue of the acquired business for the 2014 calendar year is approximately INR 1.5 billion. About 350 members of staff will transfer from UCB to Dr. Reddy's.

Alok Sonig, senior vice president and India business head of Dr. Reddy's Laboratories, said: "The acquired UCB portfolio shall accelerate Dr. Reddy's presence in the high growth areas of dermatology, respiratory and paediatrics with market leading brands like Atarax, Nootropil, Zyrtec, Xyzal, Xyzal M, etc."

UCB said the move is in line with its strategy to "provide the best value for patients and to focus on bringing them innovative drugs while ensuring its mature brands portfolio continues to reach as many people as possible." Mark McDade, UCB's chief operating officer, said: "This position allows us to focus on our neurology portfolio in India, providing innovative solutions to patients living with severe diseases."

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.